Feb 11, 2013 (M2 PRESSWIRE via COMTEX) --
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and March earnings reports. Novavax Inc (NASDAQ:NVAX), BG Medicine Inc (NASDAQ:BGMD), ArQule Inc (NASDAQ:ARQL), Federal-Mogul Corp (NASDAQ:FDML), Standard Register Co (NYSE:SR), Anthera Pharmaceuticals Inc (NASDAQ:ANTH) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Friday:
Symbol Company # of Reports Quarter Release Date
NVAX Novavax Inc March Earnings Q4 03/08/2013
BGMD BG Medicine Inc 12 Quarter Q4 03/07/2013
ARQL ArQule Inc 12 Quarter Q4 02/28/2013
FDML Federal-Mogul Corp 6 Quarter Q4 02/27/2013
SR Standard Register Co 6 Quarter Q4 02/22/2013
ANTH Anthera Pharmaceuticals Inc 6 Quarter Q4 02/21/2013
This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.
Novavax Inc (NASDAQ:NVAX) - Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particles (VLP) and recombinant nanoparticle vaccine technology. It is developing vaccine product candidates to protect against various circulating strains of pandemic influenza, including H1N1 and H5N1 influenza, as well as seasonal flu and respiratory syncytial virus (RSV). The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and manufacture the company s pandemic and seasonal influenza vaccine candidates, Cadila s biogeneric products, and other diagnostic products for the territory of India; and a licensing agreement with LG Life Sciences, Ltd. to use the company s VLP technology to develop and sell the company s influenza vaccines in South Korea and other countries. It also has a joint venture with CPL Biologics Private Limited for developing a rabies vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland..
BG Medicine Inc (NASDAQ:BGMD) - BG Medicine, Inc., a life sciences company, engages in the discovery, development, and commercialization of novel cardiovascular diagnostics to address unmet medical needs. The company markets the BGM Galectin-3, a diagnostic test for measuring galectin-3 levels in blood plasma or serum for use in patients with heart failure through regional and national laboratory testing facilities and directly to hospitals and clinics in the United States, as well as through distributors in certain countries in Europe. It is also developing CardioSCORE, a cardiovascular diagnostic test designed to identify individuals at high risk for near term cardiovascular events, such as heart attack and stroke; and galectin-3 test for a second indication to identify individuals at risk for developing heart failure, such as patients who have suffered a heart attack, as well as patients suffering from hypertension or diabetes. It has strategic collaborations with Abbott Laboratories to develop and commercialize galectin-3 assay kits and related control kits and calibrators. BG Medicine, Inc. also has development and commercialization agreements with Alere Inc., bioM rieux SA, and Siemens Healthcare Diagnostics Inc. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts..
ArQule Inc (NASDAQ:ARQL) - ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase 3 clinical trial for the treatment of non-small cell lung cancer, liver cancer, and colorectal cancer. The company also develops ARQ 621, an inhibitor of the Eg5 kinesin motor protein that has completed Phase I trial; ARQ 736, an inhibitor of the RAF kinases, which is in Phase I clinical trial; ARQ 761, an activator of the E2F-1 damage response/checkpoint pathway; and ARQ 087, an inhibitor of fibroblast growth factor receptor that is in pre-clinical stage. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in various disease indications. The company also has research collaboration with Daiichi Sankyo Co., Ltd. to discover selective inhibitors of two kinases in the field of oncology by utilizing its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts..
Federal-Mogul Corp (NASDAQ:FDML) - Federal-Mogul Corporation supplies powertrain and safety technologies worldwide. The company s Powertrain Energy segment offers powertrain components, such as engine pistons, piston rings, piston pins, cylinder liners, camshafts, valve seats and guides, and ignition products under the Federal-Mogul, AE, Champion, Goetze, Nural, and Daros brand names. Its Powertrain Sealing and Bearings segment provides dynamic seals, bonded piston seals, combustion and exhaust gaskets, static gaskets and seals, rigid heat shields, engine bearings, industrial bearings, bushings and washers, sintered engine and transmission components, and metallic filters, as well as polymer bearings primarily under the Federal-Mogul, Deva, Fel-Pro, FP Diesel, Glyco, Metafram, Metagliss, National, Payen, and Poral brand names. The company s Vehicle Safety and Protection segment offers brake disc pads, brake linings, brake blocks, element resistant systems protection sleeving products, flexible heat shields, brake system components, chassis products, windshield wipers, fuel pumps, and lighting products under the Federal-Mogul, Abex, Anco, Bentley-Harris, Beral, Champion, Ferodo, Moog, ThermoQuiet, and Wagner brands. Its Global Aftermarket segment provides aftermarket products to distributors, retail parts stores, and mass merchants who distribute these products to professional service providers and do-it-yourself consumers under the Abex, AE, ANCO, Beral, Carter, Champion, Fel-Pro, Ferodo, FP Diesel, Glyco, Goetze, MOOG, National, Necto, Nural, Payen, Sealed Power, ThermoQuiet, and Wagner brand names. The company serves original equipment manufacturers of automotive, as well as light, medium and heavy-duty commercial vehicles; and agricultural, marine, rail, aerospace, off-road, and industrial applications, as well as the aftermarket sector. The company was founded in 1899 and is headquartered in Southfield, Michigan. Federal-Mogul Corporation is a subsidiary of Icahn Enterprises L.P..
Standard Register Co (NYSE:SR) - The Standard Register Company engages in the management and execution of communications to healthcare, industrial, financial services, and commercial business markets. It operates through four segments: Healthcare, Financial Services, Commercial Markets, and Industrial. The Healthcare segment offers administrative and clinical forms, wristbands and labels, marketing solutions, secure prescriptions, patient communications, and patient information solutions. This segment s primary customers include acute care providers, long-term care providers, ambulatory care providers, payors and managed care, and facilitators of ancillary services. The Financial Services segment offers traditional documents, marketing solutions, critical communications, and software and professional services. This segment serves the needs of the financial services market consisting of retail banks, insurance carriers, credit agencies, security dealers, insurance agents or brokers, and holding companies. The Commercial Markets segment provides documents, including specialized prints, marketing solutions, labels, customer communication solutions, and digital print solutions for business-to-business or commercial markets focusing primarily on large diverse retailers, state governments, overnight delivery carriers, business service providers, and wholesale companies. The Industrial segment primarily provides printed production parts to the industrial manufacturing market. Its products and services include functional and decorative labels, in-mold labeling, decorating and printed technical literature, and other documents. The company sells its products directly, as well as through inside-sales and telesales channels, business development groups, a technology sales group, e-commerce Websites, and associates. The Standard Register Company was founded in 1912 and is based in Dayton, Ohio..
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) - Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation. The company s development programs focus on anti-inflammatory therapeutics for cardiovascular diseases, lupus, and other serious diseases. Its primary product candidates include blisibimod, which is phase II clinical trial for the treatment of systemic lupus erythematosus. The company s product candidates also comprise varespladib and varespladib sodium that are designed to inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2., which are implicated in various acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome associated with sickle cell disease, as well as in chronic diseases, such as stable coronary artery disease. It has license agreements with Eli Lilly and Company and Shionogi & Co., Ltd. to develop and commercialize sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize blisibimod for the treatment of systemic lupus erythematosus. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California..
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Thomas Ronk, CEO
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to email@example.com.